NASDAQ (usa) | 6715.56 | -12.11 | -0.18% | |
FTSE 100 (london) | 7487.96 | -5.12 | -0.07% | |
DAX (german) | 13465.51 | 235.94 | 1.78% | |
NIKKEI 225 (japan) | 22420.08 | 408.47 | 1.86% | |
Hang - Seng (hong kong) | 28594.06 | 348.52 | 1.23% |
NIFTY - 50 (india) | ||||
Straits Times (singapore) | 3391.61 | 17.53 | 0.52% | |
KOSPI (korea) | 2556.47 | 33.04 | 1.31% | |
All Ordinaries (australia) | 6005.30 | 28.90 | 0.48% | |
BOVESPA (brazil) | 74092.76 | -215.73 | -0.29% |
Cassiopea S.p.A (SW: SKIN)
SKIN Technical Analysis
5
As on 3rd Mar 2022 SKIN STOCK Price closed @ 32.50 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 46.15 & Strong Sell for SHORT-TERM with Stoploss of 46.43 we also expect STOCK to react on Following IMPORTANT LEVELS. |
SKINSTOCK Price
Open | 29.60 | Change | Price | % |
High | 36.00 | 1 Day | 2.50 | 8.33 |
Low | 25.70 | 1 Week | -0.50 | -1.52 |
Close | 32.50 | 1 Month | -1.40 | -4.13 |
Volume | 1955 | 1 Year | -17.90 | -35.52 |
52 Week High 52.00 | 52 Week Low 28.60 |
SW Switzerland Most Active Stocks
CSGN | 0.82 | 0.00% |
CSGN | 0.82 | 0.00% |
NESN | 75.96 | -0.73% |
NESN | 75.96 | -0.73% |
UBSG | 28.14 | -0.04% |
UBSG | 28.14 | -0.04% |
NOVN | 91.56 | 0.63% |
NOVN | 91.56 | 0.63% |
PRFN | 0.03 | 50.00% |
ARYN | 1.46 | -0.68% |
SW Switzerland Top Gainers Stocks
SW Switzerland Top Losers Stocks
SKIN Daily Charts |
SKIN Intraday Charts |
Whats New @ Bazaartrend |
SKIN Free Analysis |
|
SKIN Important Levels Intraday
RESISTANCE | 52.35 |
RESISTANCE | 45.98 |
RESISTANCE | 42.05 |
RESISTANCE | 38.11 |
SUPPORT | 26.89 |
SUPPORT | 22.95 |
SUPPORT | 19.02 |
SUPPORT | 12.65 |
SKIN Forecast November 2024
4th UP Forecast | 42.14 |
3rd UP Forecast | 39.05 |
2nd UP Forecast | 37.14 |
1st UP Forecast | 35.23 |
1st DOWN Forecast | 29.78 |
2nd DOWN Forecast | 27.87 |
3rd DOWN Forecast | 25.96 |
4th DOWN Forecast | 22.87 |
SKIN Weekly Forecast
4th UP Forecast | 39.63 |
3rd UP Forecast | 37.34 |
2nd UP Forecast | 35.93 |
1st UP Forecast | 34.52 |
1st DOWN Forecast | 30.48 |
2nd DOWN Forecast | 29.07 |
3rd DOWN Forecast | 27.66 |
4th DOWN Forecast | 25.37 |
SKIN Forecast2024
4th UP Forecast | 85.11 |
3rd UP Forecast | 68.24 |
2nd UP Forecast | 57.81 |
1st UP Forecast | 47.38 |
1st DOWN Forecast | 17.62 |
2nd DOWN Forecast | 7.19 |
3rd DOWN Forecast | -3.24 |
4th DOWN Forecast | -20.11 |
Cassiopea S.p.A ( SW Switzerland Symbol : SKIN )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
SKIN Other Details
Segment | EQ | |
Market Capital | 344000000.00 | |
Sector | Healthcare | |
Industry | Biotechnology | |
Offical website | > echo $website ; ?> |
SKIN Address
SKIN Latest News
SKIN Business Profile
Cassiopea S.p.A., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing medical dermatology products worldwide. It offers Winlevi, an antiandrogen, which has completed Phase III clinical trial for the topical treatment of acne; Breezula, a topical antiandrogen that is in Phase II clinical trial to treat androgenic alopecia; CB-06-01, a topical antibiotic, which is in Phase II clinical trial for the treatment of acne, including strains resistant to other antibiotics; and CB-06-02, a novel integrin activator that has completed Phase II clinical trial to treat genital warts. The company was formerly known as Cosmo Dermatos S.r.l. Cassiopea S.p.A. was founded in 2013 and is based in Lainate, Italy. Address: Via Cristoforo Colombo, 1, Lainate, MI, Italy, 20020
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service